Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin
NVIDIA Blog · Brian Caulfield · 2026-07-20
Bristol Myers Squibb announced deployment of a second NVIDIA DGX SuperPOD built on Vera Rubin NVL72 systems delivering 10x performance-per-megawatt gains, designed to give every BMS scientist unlimited access to AI compute across the full drug discovery pipeline.
Appears in
Extraction
Topics: pharmaceutical-aidrug-discoveryai-infrastructureagentic-ai
Claims
- BMS is deploying a second DGX SuperPOD on eight DGX Vera Rubin NVL72 systems that delivers up to 10x the performance per megawatt of the infrastructure it replaces.
- BMS's existing AI infrastructure has already saved scientists weeks of manual work in target identification and expanded the company's library of CELMoD cancer-targeting compounds.
- BMS's 'Predict First' methodology uses AI predictions to prioritize molecular synthesis and filter out candidates unlikely to meet target property profiles before expensive lab work begins.
- The new and existing SuperPODs will be unified into a single data plane accessible from every BMS site globally, breaking down historical site-specific data silos.
- Agentic workflows are expected to compound institutional drug discovery knowledge across programs and therapeutic areas in ways that were previously impossible.
Key quotes
Instead of equipping a small group of researchers with access to the supercomputer, we're opening it up to literally every scientist. No one has to wait, and no one is told they have a limit.
There's a cumulative learning loop today in drug discovery that did not exist when I first started my career. Every project was treated differently, and there were discrete sets of learnings that did not compound into any kind of intelligence framework within discovery.
When you as a scientist can go to an army of well-vetted, fully trained virtual scientists that have BMS knowledge baked in now you're a whole team in and of yourself.